AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00450398
Drug: YSPSL
RxNorm normalized name: YSPSL
DrugBank: rPSGL-Ig (DB06256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient prior to arterial reperfusion of the liver.
Trial: NCT04527848
Drug: small amount of undiluted C3F8
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitrectomy followed by peeling of the internal limiting membrane and, after that, intraocular gas injection
Trial: NCT03441555
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tablet, oral
Trial: NCT03441555
Drug: Alvocidib
RxNorm normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT02736955
Drug: Valbenazine
RxNorm normalized name: Valbenazine
DrugBank: Valbenazine (DB11915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00315588
Drug: Islet Transplantation
RxNorm normalized name: Autologous pancreatic islets
DrugBank: Autologous pancreatic islets (DB18521)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islet Transplantation in subjects with a previous kidney transplant.
Trial: NCT03355768
Drug: Romidepsin
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous administration on a 28 day cycle
Trial: NCT03355768
Drug: Pralatrexate
RxNorm normalized name: Pralatrexate
DrugBank: Pralatrexate (DB06813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous administration on a 28 day cycle
Trial: NCT03324503
Drug: Glucocorticoid (prednisone or prednisolone)
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ≥ 30 mg/day prednisone or prednisolone taken orally as per local clinical practice of sarcoidosis initial induction therapy
Trial: NCT00105586
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will either take 10 to 20 mg of escitalopram or placebo. Participants who wish to participate in the open-label extension receive an additional 12 weeks of escitalopram.
Trial: NCT04121039
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
Trial: NCT02917941
Drug: Ixazomib
RxNorm normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ixazomib capsules
Trial: NCT02917941
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide capsules
Trial: NCT02917941
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone Tablets
Trial: NCT00001266
Drug: Suramin
RxNorm normalized name: suramin
DrugBank: Suramin (DB04786)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00194480
Drug: Pegylated Interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly injections of pegIntereferon
Trial: NCT02005315
Drug: Vantictumab
RxNorm normalized name: Vantictumab
DrugBank: Vantictumab (DB12956)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenous (IV) infusion.
Trial: NCT02005315
Drug: Nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-Paclitaxel will be administered by intravenous (IV) infusion.
Trial: NCT02005315
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine will be administered by intravenous (IV) infusion.
Trial: NCT03132623
Drug: andrographolide sulfonate
RxNorm normalized name: Dimethyl sulfone
DrugBank: Andrographolide (DB05767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiyanping injection 10-20ml/d, With 0.9% Sodium Chloride Injection 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
Trial: NCT03132623
Drug: andrographolide sulfonate simulation
RxNorm normalized name: Dimethyl sulfone
DrugBank: Andrographolide (DB05767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiyanping injection simulation(0.9% normal saline) 10-20ml/d, The treatment method is the same as the experimental group.
Trial: NCT03734991
Drug: Ibrexafungerp
RxNorm normalized name: Ibrexafungerp
DrugBank: Ibrexafungerp (DB12471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ibrexafungerp 300 mg BID for 1 day
Trial: NCT00308399
Drug: Itopride
RxNorm normalized name: itopride
DrugBank: Itopride (DB04924)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04182880
Drug: CPL-01
RxNorm normalized name: anti-inhibitor coagulant complex
DrugBank: Anti-inhibitor coagulant complex (DB13151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPL-01 will be administered
Trial: NCT04263298
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500mg Days 0, 14, 28, then every 28 days
Trial: NCT04052997
Drug: Camidanlumab Tesirine
RxNorm normalized name: Camidanlumab tesirine
DrugBank: Camidanlumab tesirine (DB16411)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Infusion
Trial: NCT00175370
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomized double-blind equivalence trial to test the hypothesis that 2 days is equivalent to 7 days of vancomycin treatment for intravascular device associated bacteremia due to coagulase negative staphylococcus. The definitions for the surveillance of intravascular device associated bacteremia from the Laboratory Centre for Disease Control-Health Canada will be used. Surveillance blood cultures on days 4 and 9 following removal of intravascular device. Relatedness of strains will be determined by pulsed-field gel electrophoresis (PFGE).
Trial: NCT02230306
Drug: Cobimetinib
RxNorm normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 60mg once a day; will be taken on days 1-21 of each 28 day treatment cycle; will be taken in combination with Vemurafenib;
Trial: NCT02230306
Drug: Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 960mg twice a day; 28 day treatment cycle; will be taken in combination with Cobimetinib;
Trial: NCT02083679
Drug: Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of cisplatin/pemetrexed (cisplatin 75 mg/m\^2 plus pemetrexed 500 mg/m\^2 on Day 1 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
Trial: NCT02083679
Drug: Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of carboplatin/paclitaxel (carboplatin area under the concentration-time curve (AUC) = 6 milligram per millilitre per minute \[mg/mL/min\] plus paclitaxel 225 mg/m\^2 on Day 1 of 3-Week cycle intravenously for a maximum of 6 treatment cycles).
Trial: NCT02083679
Drug: Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg on Day 1 and 12 mg/kg on Day 8 of a 3-Week cycle until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of carboplatin/paclitaxel (carboplatin AUC = 6 mg/mL/min plus paclitaxel 225 mg/m\^2 on Day 1 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
Trial: NCT01220856
Drug: Reparixin
RxNorm normalized name: Reparixin
DrugBank: Reparixin (DB12614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reparixin + immunosuppression
Trial: NCT00113997
Drug: REG1
RxNorm normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00116402
Drug: fluticasone and salmeterol
RxNorm normalized name: Fluticasone and salmeterol only product
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1. will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID~2. will start with salmeterol 50 mcg BID first and then crossover to combination therapy with fluticasone 220 mcg BID.
Trial: NCT02176837
Drug: Sodium Nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive continuous intravenous infusion of study drug for 7 days at a dose of 64 nmol/min/kg. The infusion will begin shortly after angiographic demonstration of cerebral vasospasm and will be for 7 days unless side effects of the drug dictate stopping the infusion.
Trial: NCT03421496
Drug: Cannabidiol Oral Solution
RxNorm normalized name: cannabidiol Oral Solution
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
Trial: NCT03421496
Drug: Vigabatrin
RxNorm normalized name: Vigabatrin
DrugBank: Vigabatrin (DB01080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Powder suspension
Trial: NCT00238732
Drug: Bazedoxifene/Conjugated Estrogen
DrugBank: Bazedoxifene (DB06401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02716038
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin is a second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. Carboplatin area under the curve (AUC)=6 will be administered as a 30 minute IV infusion immediately after nab-paclitaxel.
Trial: NCT02716038
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Nab-paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. Nab-paclitaxel 100 mg/m2 will be administered as a 30 minute IV infusion.
Trial: NCT03036059
Drug: 400 μg/kg Ivermectin + 400 mg Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400ug/Kg, tablet, given orally once or twice a year.
Trial: NCT00650143
Drug: Lenograstim (GRANOCYTE)=GCSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg/kg/d s.c. for 5 days divided in two dosages per day
Trial: NCT00650143
Drug: Sitagliptin (Januvia)
RxNorm normalized name: sitagliptin Oral Tablet [Januvia]
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg p.o. per day for 28 days
Trial: NCT00650143
Drug: Sodium Chloride (NaCl) 0.9 %
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: applied s.c. twice a day for 5 days
Trial: NCT00650143
Drug: Gelatin
RxNorm normalized name: Gelatin
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule p.o. per day for 28 days
Trial: NCT04360434
Drug: NI006
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NI006 will be administered intravenously
Trial: NCT00691678
Drug: Chondroitin
RxNorm normalized name: Chondroitin
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg chondroitin three times a day (TID) for twenty-four weeks
Trial: NCT00618917
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy to stop the growth of tumor cells.
Trial: NCT00618917
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy to stop the growth of tumor cells. This drug kills tumor cells by inducing multipolar divisions. Cells entering mitosis in the presence of concentrations of paclitaxel equivalent to those in human breast tumors form abnormal spindles that contain additional spindle poles.
Trial: NCT01218425
Drug: Methylphenidate 40 mg
RxNorm normalized name: dexmethylphenidate 40 mg oral capsule, extended release
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dose 40 mg
Trial: NCT01218425
Drug: Domperidon 10 mg
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidon 10 mg
Trial: NCT01684111
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
Trial: NCT01811498
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02925234
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of panitumumab might be expected based on their molecular tumor profile.
Trial: NCT02925234
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of olaparib might be expected based on their molecular tumor profile.
Trial: NCT02925234
Drug: Dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of dabrafenib might be expected based on their molecular tumor profile.
Trial: NCT02925234
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nilotinib might be expected based on their molecular tumor profile.
Trial: NCT02925234
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trametinib might be expected based on their molecular tumor profile.
Trial: NCT02925234
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of erlotinib might be expected based on their molecular tumor profile.
Trial: NCT02925234
Drug: Trastuzumab and Pertuzumab (combination treatment)
RxNorm normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab and Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trastuzumab + pertuzumab might be expected based on their molecular tumor profile.
Trial: NCT02925234
Drug: Vemurafenib and Cobimetinib (combination treatment)
RxNorm normalized name: Vemurafenib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Vemurafenib + Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib + Cobimetinib might be expected based on their molecular tumor profile.
Trial: NCT02925234
Drug: Vismodegib
RxNorm normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.
Trial: NCT02925234
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.
Trial: NCT02925234
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nivolumab might be expected based on their molecular tumor profile.
Trial: NCT02925234
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Afatinib might be expected based on their molecular tumor profile.
Trial: NCT02925234
Drug: Dabrafenib and trametinib
RxNorm normalized name: Dabrafenib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib + trametinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Dabrafenib + Trametinib might be expected based on their molecular tumor profile.
Trial: NCT02925234
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ribociclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Ribociclib might be expected based on their molecular tumor profile.
Trial: NCT02925234
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Lenvatinib might be expected based on their molecular tumor profile.
Trial: NCT02925234
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Pembrolizumab might be expected based on their molecular tumor profile.
Trial: NCT02925234
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Durvalumab might be expected based on their molecular tumor profile.
Trial: NCT02925234
Drug: Rucaparib
RxNorm normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rucaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Rucaparib might be expected based on their molecular tumor profile.
Trial: NCT02925234
Drug: Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Axitinib might be expected based on their molecular tumor profile.